← FDA ENFORCEMENT
D-0043-2025Class II

Cipla USA, Inc.

Recalling firm
Cipla USA, Inc.
Product type
Drug
Status
Ongoing
Report date
2024-11-20
Distribution
USA nationwide.
Firm state
NJ
Product quantity
1,875 boxes (cipla and exlan)
Initiated by
Voluntary: Firm initiated
Reason for recall

Failed Tablet/Capsule Specifications: Complaints received of crushed and broken tablets.

Product description

Lanthanum Carbonate Chewable Tablets, 1000mg, 10-count bottle, Rx only, Manufactured for Cipla USA, NDC 69097-0936-98

Code / lot info

Lot # NB240316, Exp 12/31/25

Data: U.S. FDA openFDA enforcement API. Recall details are as reported by the FDA. The quality-domain mapping and severity are a SPEQ editorial interpretation of the recall reason, not an official FDA classification.